Price List - Selarsdi - TIB - IL23.xlsx

XLSX spreadsheet 50 KB Posted

Attached to
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Solicitation number
HT9402-25-Q-9202
Issued by

About this file

This is a pricing template spreadsheet for the Department of Defense (DoD) Pharmacy Uniform Formulary program, specifically for Targeted Immunomodulatory Biologics - Interleukin 23 drugs to be reviewed at the May 7-8, 2025 DoD Pharmacy & Therapeutics Committee meeting. The template includes pricing sections for both Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) quotes.

The template provides pricing scenarios for up to 10 newly approved drugs, with quotes due by March 20, 2025. It includes formulary placement options (Uniform Formulary, Non-Formulary) and step therapy categories (Before Step, After Step) for Military Treatment Facilities and Mail Order. The ADP section allows manufacturers to provide additional retail refunds based on either non-FAMP (Federal Average Manufacturer Price) or WAC (Wholesale Acquisition Cost) pricing. Prior authorization requirements may apply, and the DoD P&T Committee will consider removing step therapy preferences for certain indications like psoriasis and IBD. The template itself does not specify actual products or prices, as it is designed for manufacturers to input their quotes.

View the file

Other files

File Type Posted
RFQ HT9402-25-Q-9202 NAD.pdf PDF
Price List - Steqeyma - TIB - IL23.xlsx XLSX spreadsheet
Price List - Journavx - Pain Agents - Pain Misc..xlsx XLSX spreadsheet
Price List - Prevymis - Antivirals - NA.xlsx XLSX spreadsheet
Price Appendix FAQ NAD.pdf PDF
Price List - Yesintek - TIB - IL23.xlsx XLSX spreadsheet
DoD Formulary Placement of FDA Newly Approved Drugs.pdf PDF

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

BPA

UF BPA NDC Price List for the May 2025 DoD P&T Meeting
DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
Formulary Notes
Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The DoD P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the DoD P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service.

Biosimilar Step Therapy Addendum: Since biosimilars are equivalent to the reference product, no grandfathering will apply. No Grandfathering: a prior authorization may process require new and current patients to complete an adequate trial of the step-preferred biosimilar(s) before a non-step-preferred biosimilar is provided to the patient at any MTF, Retail, or Mail point of service.

All Scenarios:

•P&T will consider removing the TIBS class step preference (i.e., adalimumab) for select indications (e.g., psoriasis, IBD).
•Agents with RFQ not submitted or selected may be designated non-step preferred.

Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.

The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.

Blanket Purchase Agreement Appendix – Newly Approved Drug

#1DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
One agent UF and before the step.
Scenario 1251TB23G1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
251TB23G1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
251TB23G1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#2DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
One agent UF and before the step.
Scenario 1251TB23G1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
251TB23G1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
251TB23G1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#3DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
One agent UF and before the step.
Scenario 1251TB23G1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
251TB23G1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
251TB23G1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#4DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
One agent UF and before the step.
Scenario 1251TB23G1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
251TB23G1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
251TB23G1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#5DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
One agent UF and before the step.
Scenario 1251TB23G1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
251TB23G1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
251TB23G1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#6DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
One agent UF and before the step.
Scenario 1251TB23G1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
251TB23G1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
251TB23G1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#7DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
One agent UF and before the step.
Scenario 1251TB23G1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
251TB23G1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
251TB23G1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#8DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
One agent UF and before the step.
Scenario 1251TB23G1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
251TB23G1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
251TB23G1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#9DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
One agent UF and before the step.
Scenario 1251TB23G1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
251TB23G1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
251TB23G1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#10DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
One agent UF and before the step.
Scenario 1251TB23G1UFBS1Uniform Formulary
Before Step Therapy1NO QUOTE
251TB23G1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
251TB23G1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

ADP (non-FAMP Discount)

UF ADP Appendix for the May 2025 DoD P&T Meeting
DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
Formulary Notes
Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The DoD P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the DoD P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service.

Biosimilar Step Therapy Addendum: Since biosimilars are equivalent to the reference product, no grandfathering will apply. No Grandfathering: a prior authorization process may require new and current patients to complete an adequate trial of the step-preferred biosimilar(s) before a non-step-preferred biosimilar is provided to the patient at any MTF, Retail, or Mail point of service.

All Scenarios:

•P&T will consider removing the TIBS class step preference (i.e., adalimumab) for select indications (e.g., psoriasis, IBD).
•Agents with RFQ not submitted or selected may be designated non-step preferred.

Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.

* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.

Additional Discount Program Appendix – Newly Approved Drug

#1DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
One agent T2 and before the step.
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#2DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
One agent T2 and before the step.
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#3DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
One agent T2 and before the step.
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#4DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
One agent T2 and before the step.
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#5DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
One agent T2 and before the step.
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#6DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
One agent T2 and before the step.
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#7DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
One agent T2 and before the step.
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#8DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
One agent T2 and before the step.
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#9DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
One agent T2 and before the step.
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#10DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
One agent T2 and before the step.
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

ADP (WAC Discount)

UF ADP Appendix for the May 2025 DoD P&T Meeting
DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
Formulary Notes
Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The DoD P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the DoD P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service.

Biosimilar Step Therapy Addendum: Since biosimilars are equivalent to the reference product, no grandfathering will apply. No Grandfathering: a prior authorization process may require new and current patients to complete an adequate trial of the step-preferred biosimilar(s) before a non-step-preferred biosimilar is provided to the patient at any MTF, Retail, or Mail point of service.

All Scenarios:

•P&T will consider removing the TIBS class step preference (i.e., adalimumab) for select indications (e.g., psoriasis, IBD).
•Agents with RFQ not submitted or selected may be designated non-step preferred.

Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.

The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).

WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.

*The quoted WAC Discount percentage will remain static during the life of the agreement.

Additional Discount Program Appendix – Newly Approved Drug

#1DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
One agent T2 and before the step.
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#2DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
One agent T2 and before the step.
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#3DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
One agent T2 and before the step.
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#4DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
One agent T2 and before the step.
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#5DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
One agent T2 and before the step.
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#6DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
One agent T2 and before the step.
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#7DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
One agent T2 and before the step.
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#8DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
One agent T2 and before the step.
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#9DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
One agent T2 and before the step.
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#10DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 7-8, 2025
DOD Uniform Formulary Subclass:INTERLEUKIN 23Quotes due:March 20, 2025
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
One agent T2 and before the step.
Scenario 1251TB23G1T2BS1Tier 2
Before Step Therapy1
251TB23G1T2AS1MTier 2
After Step Therapy1 or more
251TB23G1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

File details come from the government source that posted it. Updated .